ÂÜÀòÂÒÂ×

Dr René Kuijten joined LSP in 2001 and is Managing Partner. René has founded and supported many life sciences companies as a supervisory board director, twelve of which have been acquired or have listed on international stock exchanges. Among others, he was involved in Kudos, sold to AstraZeneca, which developed Olaparib, one of the most successful new cancer treatments of today, and Neuravi, sold to J&J, with an innovative stroke therapy. His most recent exit was Simplify Medical (Australia) working on cervical discs, sold to Nuvasive. He is currently on the board of Artios Pharma (UK), active in the area of DNA repair and Amolyt Pharma (France), focusing on rare diseases. As Managing Partner, René is also actively involved in the strategic planning, general management and fundraising of LSP; he was instrumental in raising the LSP 3 - 6 funds and he founded two new strategies for LSP: the Health Economics Funds and the LSP Dementia Fund.